Published 4 days ago • loading... • Updated 4 days ago

DEM BioPharma Announces Poster Presentation Featuring DEM301 at the 2026 ASCO Gastrointestinal Cancers Symposium

At the Gastrointestinal Cancers Symposium 2026 in San Francisco, Bexion Pharmaceuticals, Inc. will present Phase 1b/2 data on BXQ-350 combined with mFOLFOX7 and bevacizumab.
The program builds on multiple Phase 1 clinical trials showing a robust safety profile and single-agent activity for BXQ-350, while Bexion Pharmaceuticals is developing biologics for solid tumors and CIPN.
Session details list Dr. Reema Patel , Dr. Tariq Arshad, and Michael Gazda for Saturday, January 10, 2026, with Abstract 105 and Abstract 242 posters.
Additional data indicate BXQ-350 shows activity against oxaliplatin-induced chemotherapy-induced peripheral neuropathy, and enrollment is complete for the open-label portion of the Phase 1b/2 study and proof-of-concept CIPN trial.
The abstracts were posted to the ASCO GI Online Program at 5 PM ET on Jan. 6, 2026, with details in the company's release and poster listings.

Insights by Ground AI

49 Articles

Bennington Banner

+47 Reposted by 47 other sources

Center

Bexion Pharmaceuticals, Inc. Announces Poster Presentations at the American Society for Clinical Oncology (ASCO) Gastrointestinal Cancers Symposium 2026

COVINGTON, Ky., Jan. 6, 2026 /PRNewswire/ -- Bexion Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company developing a novel class of biologic therapy to treat solid tumor cancers and chemotherapy-induced peripheral neuropathy (CIPN), today announced that the Company will participate in the…

4 days ago

Read Full Article